4.7 Article

Targeting Myddosome Signaling in Waldenstrom's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191

期刊

CLINICAL CANCER RESEARCH
卷 24, 期 24, 页码 6408-6420

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-17-3265

关键词

-

类别

资金

  1. National Cancer Institute [R01 CA194264, R01 CA184464, P50 CA142509, U10 CA032102]
  2. Leukemia & Lymphoma Society [SCOR-12206-17]
  3. MD Anderson Cancer Center Support Grant [P30 CA016672]
  4. NATIONAL CANCER INSTITUTE [P50CA142509, P30CA016672, R01CA184464, R01CA194264, U10CA032102] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Purpose: Waldenstrom's macroglobulinemia is an incurable lymphoproliferative disorder driven by an L265P mutation in the myeloid differentiation primary response gene 88 (MYD88), which activates downstream NF-kappa B signaling through the Myddosome. As this pathway depends in part on activity of interleukin-1 receptor-associated kinases (IRAKs)-1 and -4, we sought to evaluate the potential of the IRAK1/4 inhibitor R191 in preclinical models. Experimental Design: Patient-derived cell lines and primary samples were used in both in vitro and in vivo experiments to model Waldenstrom's macroglobulinemia and its response to IRAK1/4 inhibitors. Results: R191 induced a dose-and time-dependent reduction in viability of BCWM. 1 and MWCL-1 Waldenstrom's cell lines, and suppressed activation of IRAK1/4. This was associated with cell-cycle arrest at G(0)-G(1), reduced levels of cyclin-dependent kinases 4 and 6, and induction of apoptosis in cell lines and primary patient samples. Further downstream, R191 exposure led to reduced activation of NF-kappa B, and of protein kinase B/Akt/mammalian target of rapamycin signaling, whereas expression of a constitutively active Akt mutant induced R191 resistance. Gene expression profiling and gene set enrichment analysis revealed a signature consistent with inhibition of c-Myc and activation of the endoplasmic reticulum stress response. In both subcutaneous and systemic murine models of Waldenstrom's, R191 showed antitumor activity. Finally, the activity of R191 was enhanced when it was combined with novel chemotherapeutics such as bortezomib, afuresertib, and ibrutinib. Conclusions: Taken together, these data support the translation of R191 as an approach to target IRAK1/4 to the clinic for patients with Waldenstrom's macroglobulinemia. (C) 2018 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据